Last edition
News about "Medicxi"
D3 Bio Secures USD 108 Million in Series B Financing to Advance Global Clinical Programmes
D3 Bio has raised USD 108 million in Series B financing to advance its global clinical programmes. The funds will support the Phase III pivotal trial of its lead asset, elisrasib (D3S-001), while also accelerating the development of the company’s broader pipeline of targeted and immuno-oncology therapies with first-in-class and best-in-class potential.
Medicxi | 11/12/2025 | By Akanki
Servier to Acquire KER-0193 from Kaerus Bioscience in Deal Worth Up to USD 450 Million
Servier has signed a definitive agreement to acquire KER-0193 from Kaerus Bioscience, a potential first-in-disease treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder.
Medicxi | 08/09/2025 | By Mrinmoy Dey | 117
Sanofi to Acquire Vicebio for USD 1.6 Billion
Sanofi has entered into a definitive agreement to acquire Vicebio Ltd., a biopharma company developing next-generation respiratory vaccines, in a deal worth up to USD 1.6 billion, including an upfront payment of USD 1.15 billion.
Medicxi | 22/07/2025 | By Mrinmoy Dey | 272
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy